AI MARKET SCANNING

Oruka Therapeutics Inc

📅 Next Catalyst: Nov 11, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +2.00%
MAX GAP RECORD +8.03%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ORKA
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 11, 2026 Earnings Release 2026-11-11 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 10, 2026 Earnings Release 2026-08-10 (AFTER CLOSE)
+2.29%
May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE)
+0.28%
Mar 12, 2026 Earnings Release 2026-03-12 (AFTER CLOSE)
+2.66%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
+5.27%
Aug 11, 2025 Earnings Release 2025-08-11 (AFTER CLOSE)
+1.30%
May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE)
+8.03%
Mar 06, 2025 Earnings Release 2025-03-06 (AFTER CLOSE)
-0.89%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.0%
Bullish Gaps (5)
Bearish Gaps (1)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ORKA

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗